DLI has less efficacy in other hematologic diseases, with response rates of approximately 20-30% for other diseases including acute myeloid leukemia (AML), ...
Missing: decides | Show results with:decides
Feb 1, 2018 · Their 2-year survival rate was 29.7%. Recipients of donor lymphocytes achieved a median survival from first infusion of 6.0 months (95% ...
Nov 17, 2023 · Chronic myelogenous leukemia treatment may include targeted therapy, immunotherapy, chemotherapy, stem cell transplant, donor lymphocyte ...
Apr 8, 2021 · DLI is the treatment of choice for CML patients in relapse after allogeneic HSCT, with the seminal work of Kolb et al. demonstrating the ...
Its curative potential is mostly attributed to the graft-versus-leukemia effect (GvL), which is mainly driven by donor T-cells. Donor lymphocyte infusions (DLI) ...
Aug 1, 2023 · They can potentially directly target leukemic cells. Thus, DLIs can be given to acute myeloid leukemia (AML) patients after allogeneic ...
Apr 1, 2021 · Median survival for patients receiving a first dose of DLI “preemptively,” in the absence of relapse and guided by risk marker monitoring ( ...
Nov 17, 2023 · Targeted therapy; Chemotherapy; Immunotherapy; High-dose chemotherapy with stem cell transplant; Donor lymphocyte infusion (DLI); Surgery. New ...
Jul 22, 2022 · In addition to presenting with de novo BP-CML, patients may progress on therapy. With the introduction of BCR-ABL1-specific tyrosine kinase ...
If relapse is picked up on a bone marrow test or in the blood and there is higher level of disease, chemotherapy will be used first followed by a DLI to help ...